Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: ILMN

Illumina, Inc.

Healthcare | Medical - Diagnostics & Research

Market prices for ILMN are shown to signed-in users (sign in). This public page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$5.36

Illumina, Inc. (NASDAQ: ILMN) is a diagnostics and research company. Figures from SEC EDGAR; updated 2026-10-20 05:59 UTC.

What Illumina, Inc. does

The company provides sequencing and array-based solutions for genetic and genomic analysis used by research centers, academic institutions, government laboratories, hospitals, and pharmaceutical and biotechnology companies. Its integrated portfolio includes sequencing systems, microarray systems, consumables, and analysis tools designed for various genomic applications and customer needs. The company was incorporated in California in April 1998 and reincorporated in Delaware in July 2000, with principal offices in San Diego, California.

Summarized from Illumina, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation
EPS (TTM)$5.36
Return on equity31.22%
Debt/equity0.18

Revenue, margins & earnings

FY2021 Revenue: $4.53B — margin split not shown (non-operating gains)$4.53BFY2021FY2022: net loss $4.40B on revenue $4.58B$4.58BFY2022FY2023: net loss $1.16B on revenue $4.50B$4.50BFY2023FY2024: net loss $1.22B on revenue $4.37B$4.37BFY2024FY2025 Revenue: $4.34B — margin split not shown (non-operating gains)$4.34BFY2025
  • Net income
  • Taxes & interest
  • Operating expenses
  • Cost of revenue
  • Net loss year
Annual revenue; bands show net, operating, gross margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-10-07
  • 2026-10-07Chief Executive OfficerTax withholding-1,303$382.7K
  • 2026-10-02DirectorAward107$23.5K
  • 2026-10-02DirectorAward113$24.8K
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Illumina, Inc. do?

The company provides sequencing and array-based solutions for genetic and genomic analysis used by research centers, academic institutions, government laboratories, hospitals, and pharmaceutical and biotechnology companies.

When did ILMN last file with the SEC?

Illumina, Inc.'s most recent SEC filing on record is a 8-K filed 2026-10-13. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 05:59 UTC. This page is also available as JSON at /api/data?ticker=ILMN and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for ILMN and 5,000+ tickers.

Create a free account — keep ILMN
For your agent
GET /api/data?ticker=ILMN

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt